Humana's Q3 2020 earnings were impacted by increasing utilization, COVID-19 testing and treatment costs, and crisis relief efforts. The company reported GAAP EPS of $10.05 and Adjusted EPS of $3.08. Humana anticipates fourth quarter losses to reflect continued support for its constituents, along with the impact of increasing utilization, and COVID-19 testing and treatment costs.
Continued emphasis on actions to alleviate financial burdens and other hardships for its members, providers, employees, and communities during the COVID-19 pandemic.
Achieved 92 percent, or 4.1 million of the company's Medicare Advantage members currently enrolled in 4-Star and above contracts for 2021, including 960,000 members in 4.5 Star contracts and a 5-Star rated contract in Florida.
Reported 3Q20 earnings per diluted common share (EPS) of $10.05 on a GAAP basis, $3.08 on an Adjusted basis; reports YTD 2020 EPS of $27.37 on a GAAP basis, $21.04 on an Adjusted basis
Increased full year expected individual Medicare Advantage membership growth to approximately 375,000 members from the previous range of 330,000 to 360,000 members, representing expected year-over-year growth of approximately 10 percent
Humana adjusted its GAAP and Adjusted EPS guidance ranges for the year ended December 31, 2020 (FY20).